title: Chronic myelomonocytic leukemia in the light of the WHO proposals.
abstract: The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. To confirm these proposals, we analyzed 266 patients with CMML I and 73 patients with CMML II. Median survival time was 20 months for CMML I, and 15 months for CMML II (p<0.005). The cumulative risk of AML evolution differed between patient groups (p=0,001). No conclusive differences in clinical, morphologic, hematologic or cytogenetic parameters were found. These data support the WHO proposals for the classifi-cation of CMML.
authors.affiliation: Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. germing@med.uni-duesseldorf.de
authors.forename: Ulrich
authors.initials: U
authors.lastname: Germing
authors.forename: Corinna
authors.initials: C
authors.lastname: Strupp
authors.forename: Sabine
authors.initials: S
authors.lastname: Knipp
authors.forename: Andrea
authors.initials: A
authors.lastname: Kuendgen
authors.forename: Aristoteles
authors.initials: A
authors.lastname: Giagounidis
authors.forename: Barbara
authors.initials: B
authors.lastname: Hildebrandt
authors.forename: Carlo
authors.initials: C
authors.lastname: Aul
authors.forename: Rainer
authors.initials: R
authors.lastname: Haas
authors.forename: Norbert
authors.initials: N
authors.lastname: Gattermann
authors.forename: John M
authors.initials: JM
authors.lastname: Bennett
mesh_terms: D002965:Classification; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000145:classification*; D009196:Myeloproliferative Disorders / Q000145:classification; D014944:World Health Organization